How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Noninvasive Prenatal Gene Testing Technology Market
- By Technology: Next-Generation Sequencing (NGS), Microarray Analysis, Digital PCR, Massively Parallel Sequencing (MPS), Targeted Sequencing
- By Application: Chromosomal Aneuploidy Detection, Single-Gene Disorder Detection, Sex Chromosome Aneuploidy Detection, Microdeletion and Microduplication Syndromes, Rh Blood Group Genotyping
- By Sample Type: Maternal Plasma Cell-Free DNA, Amniotic Fluid, Chorionic Villus Sampling (CVS), Maternal Serum
- By End User: Diagnostic Laboratories, Hospitals and Clinics, Specialized Prenatal Testing Centers, Research Institutes
- By Test Type: Screening Tests, Diagnostic Tests, Carrier Screening, Noninvasive Paternity Testing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Next-Generation Sequencing (NGS) leads By Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Noninvasive Prenatal Gene Testing Technology Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Technology 5
Application 5
Sample Type 4
End User 4
Test Type 4
Companies profiled
Illumina Inc.
Natera Inc.
BGI Genomics
Myriad Genetics Inc.
Invitae Corporation
F. Hoffmann-La Roche AG
PerkinElmer Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings (LabCorp)
Thermo Fisher Scientific Inc.
Sema4
Ariosa Diagnostics (a Roche company)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Natera Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →BGI Genomics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Myriad Genetics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Invitae Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →F. Hoffmann-La Roche AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PerkinElmer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Quest Diagnostics Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Laboratory Corporation of America Holdings (LabCorp)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Thermo Fisher Scientific Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sema4
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ariosa Diagnostics (a Roche company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cooperative of Genetic Testing Laboratories (CGL)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Berry Genomics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Gene by Gene
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,197M by 2033 · 9.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Next-Generation Sequencing (NGS)43.2
- Microarray Analysis17.7
- Digital PCR17.4
- Massively Parallel Sequencing (MPS)10.6
- Targeted Sequencing11.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,183M → $2,179M · 7.9%
Europe$824.8M → $1,665M · 9.2%
Asia Pacific$753.0M → $1,662M · 10.4%
Latin America$466.2M → $1,030M · 10.4%
Middle East and Africa$358.6M → $783.7M · 10.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.052026
9.072027
9.072028
9.082029
9.092030
9.112031
9.122032
9.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Illumina Inc.22.1
- Natera Inc.21.6
- BGI Genomics3.9
- Myriad Genetics Inc.4.1
- Invitae Corporation10.5
- F. Hoffmann-La Roche AG9.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Technology28.7%
Application16.8%
Sample Type13.8%
End User11.8%
Test Type29.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.8
- Europe22.7
- Asia Pacific22.7
- Latin America14.1
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Illumina Inc. | 77 | 96 | 87 | 96 | 86 | 83 | 88 |
| Natera Inc. | 81 | 74 | 89 | 72 | 77 | 80 | 79 |
| BGI Genomics | 64 | 64 | 84 | 71 | 72 | 86 | 74 |
| Myriad Genetics Inc. | 73 | 82 | 71 | 64 | 77 | 57 | 71 |
| Invitae Corporation | 76 | 67 | 59 | 60 | 58 | 60 | 63 |
| F. Hoffmann-La Roche AG | 69 | 57 | 64 | 46 | 49 | 68 | 59 |
| PerkinElmer Inc. | 45 | 63 | 51 | 65 | 59 | 50 | 56 |
| Quest Diagnostics Incorporated | 46 | 46 | 35 | 43 | 52 | 59 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Illumina Inc.
- Natera Inc.
- BGI Genomics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Illumina Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Natera Inc. | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| BGI Genomics | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Myriad Genetics Inc. | ◐ | ◐ | ✓ | ◐ | ◐ | − |
| Invitae Corporation | ✓ | − | − | ◐ | ◐ | ◐ |
| F. Hoffmann-La Roche AG | ✓ | − | − | ◐ | − | ◐ |
| PerkinElmer Inc. | − | ◐ | ◐ | ◐ | − | − |
| Quest Diagnostics Incorporated | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Illumina Inc.88
2Natera Inc.79
3BGI Genomics74
4Myriad Genetics Inc.71
5Invitae Corporation63
6F. Hoffmann-La Roche AG59
7PerkinElmer Inc.56
8Quest Diagnostics Incorporated47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Illumina Inc.Natera Inc.
Challenger2
Strong scale, closing on the leaders.
BGI GenomicsMyriad Genetics Inc.
Contender2
Focused players with pockets of strength.
Invitae CorporationF. Hoffmann-La Roche AG
Niche2
Specialists in a single segment or region.
PerkinElmer Inc.Quest Diagnostics Incorporated
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technology in North America, then scale across Noninvasive Prenatal Gene Testing Technology Market — a $212M beachhead inside a $4.30B market.
Beachhead (SOM)$212Mobtainable near-term
Serviceable (SAM)$1.51Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Next-Generation Sequencing (NGS)
Best fit — highest urgency & budget in Technology.
Economic buyer80 fit
Microarray Analysis
Strong fit — clear ROI and a fast path to value.
End user69 fit
Digital PCR
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sample Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Noninvasive Prenatal Gene Testing Technology Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified26%
Evaluation13%
Closed-won7%
$14.2KCAC
$73KLTV
5.1:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Noninvasive Prenatal Gene Testing Technology Market is a high-growth opportunity — $2.53B by 2033, compounding at 10.4%.
TAM · 2025$1.15Btoday
TAM · 2033$2.53Bforecast
CAGR10.4%2027–2033
Cumulative$15.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.53BTotal addressable market
SAM$972MServiceable available market
SOM$209MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.53BLarge & growingTAM by 2033 at 10.4% CAGR
$972MServiceable nowreachable with today’s model
$209MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.98BBear6.7% CAGR
$2.53BBase10.4% CAGR
$3.24BBull13.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Noninvasive Prenatal Gene Testing Technology Market — a $4.47B market by 2033. Plan: grow share from 9.2% to 15.3%.
Market size · 2033$4.47Btotal addressable
Market CAGR7.7%2027–2033
Target share15.3%from 9.2% today
Revenue ambition$683Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.2% | 15.3% | On track |
| Revenue | $446M | $683M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.5% | 44.6% | Ahead |
| Customer retention | 88.3% | 95.9% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $81M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Noninvasive Prenatal Gene Testing Technology Market conversation — a $10.4B market you can size, segment and defend in minutes.
Market size · 2033$10.4Btotal opportunity
Growth11.4%CAGR to 2033
Addressable buyers1,538+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology
Goal Grow share in Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 4 mopayback period
$88K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Illumina Inc.Natera Inc.BGI GenomicsMyriad Genetics Inc.Invitae CorporationF. Hoffmann-La Roche AGPerkinElmer Inc.Quest Diagnostics Incorporated+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Noninvasive Prenatal Gene Testing Technology Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Noninvasive Prenatal Gene Testing Technology Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Non-invasive Positive Pressure Ventilators (In-Home Use) Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportNoninvasive Positive-pressure Ventilation Market
Market size, share, segmentation and regional forecast.
$501M market · 2025 base year
View reportNon-Invasive Positive Pressure Ventilation Devices Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportNon-invasive Photoacoustic Imaging Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportNon-invasive Pelvic Organ Prolapse Apparel Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportNon-invasive Patient Monitor Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportNon-Invasive Neuromodulatory Devices Market
Market size, share, segmentation and regional forecast.
$534M market · 2025 base year
View reportNon-invasive Neuromodulation Device Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportNon-invasive Neonatal Ventilator Market
Market size, share, segmentation and regional forecast.
$676M market · 2025 base year
View reportNon-Invasive Neonatal Intensive Care Unit Ventilator Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportNoninvasive Mechanical Ventilation Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportNon-Invasive Liquid Biopsy Market
Market size, share, segmentation and regional forecast.
$365M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.